<DOC>
	<DOC>NCT02951091</DOC>
	<brief_summary>In-depth understanding of molecular characteristics of gastric cancer enabled us to realize personalized medicine with targeted agents in gastric cancer treatment.The investigators initiated open-label, randomized, controlled phase II, multi-arm trial comparing targeted therapy based on tumor molecular profiling with standard paclitaxel therapy as second line treatment.</brief_summary>
	<brief_title>Biomarker-Integrated Umbrella, Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1. Histologically or cytologically confirmed locally advanced or metastatic gastric cancer and gastroesophageal junction cancer 2. Eastern Cooperative Oncology Group performance status of 0 to 1 3. Male or female; ≥ 19 years of age 4. On or progression after 1st line palliative chemotherapy 5. Subjects with evaluable lesion (using RECIST 1.1 criteria) 6. Subjects who meet the following criteria: Absolute neutrophil count ≥ 1000 /µL Platelet count ≥ 75,000/ µL Serum creatinine &lt; 1.5 x upper limit of normal or Creatinine clearance ≥60 mL/min aspartate aminotransferase and alanine transaminase 3 x upper limit of normal Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>